Table 2 Comparison of characteristics in patients with and without pain after TACE
From: Construction of pain prediction model for patients undergoing hepatic arterial chemoembolization
Variables | Post-TACE pain | p value | |
|---|---|---|---|
Yes (n = 100) | No (n = 128) | ||
Male | 80 (80.0) | 94 (73.4) | 0.247 |
Age, years | 58.5 ± 10.3 | 62.3 ± 9.9 | 0.004 |
Age ≥ 60 years | 46 (46.0) | 82 (64.1) | 0.006 |
ECOG score | 0.102 | ||
0 ~ 1 | 92 (92.0) | 124 (96.9) | |
2 | 8 (8.0) | 4 (3.1) | |
History of chronic liver disease | 92 (92.0) | 116 (90.6) | 0.716 |
Previous post-TACE response | 66 (66.0) | 82 (64.1) | 0.761 |
Intraoperative super-selected target vessels during TACE | 96 (96.0) | 120 (93.8) | 0.450 |
Child–Pugh score | 0.757 | ||
Stage A | 70 (70.0) | 92 (71.9) | |
Stage B | 30 (30.0) | 36 (28.1) | |
Tumor location | 0.005 | ||
Distance from liver capsule ≤ 1 cm | 86 (86.0) | 90 (70.3) | |
Distance from liver capsule > 1 cm | 14 (14.0) | 38 (29.7) | |
Tumor size | 0.001 | ||
< 5 cm | 38 (38.0) | 76 (59.4) | |
≥ 5 cm | 62 (62.0) | 52 (40.6) | |
Number of tumors | 0.343 | ||
1 | 64 (64.0) | 74 (57.8) | |
≥ 2 | 36 (36.0) | 54 (42.2) | |
CNLC | < 0.001 | ||
Ia | 0 (0.0) | 1 (0.8) | |
Ib | 20 (20.0) | 47 (36.7) | |
IIa | 8 (8.0) | 24 (18.8) | |
IIb | 28 (28.0) | 28 (21.9) | |
IIIa | 38 (38.0) | 20 (15.6) | |
IIIb | 6 (6.0) | 8 (6.3) | |
Using drug-loaded microspheres | 20 (20.0) | 12 (9.4) | 0.022 |
Dosage of ultra-liquefied lipiodol | 0.301 | ||
< 10 ml | 92 (92.0) | 122 (95.3) | |
≥ 10 ml | 8 (8.0) | 6 (4.7) | |
THP mixed lipiodol chemoembolization | 16 (16.0) | 12 (9.4) | 0.130 |
Add embolic material | 80 (80.0) | 94 (73.4) | 0.247 |
PVTT | 40 (40.0) | 26 (20.3) | 0.001 |